Arch Therapeutics Inc (ARTH)

[divea]

Here is a summary. If you want a full report read the script from his annual report. Read every word.
First he will give a corporate overview......incorporated in Nevada...2009 to pursue business of distributing auto parts online...merge...abandoned business plan...new business plan biotech.
Then he will focus on current business of biotech focused on homeostasis..AC5. He will tout the results of the one and only clinical trial of a 30 day study on 46 patients in Ireland. He will tell how difficult it is to manufacture and formulate self-assembling peptides.
He probably won't mention the NUIG contract or how Dr. Rutledge Ellis-Behnke retains ownership of all intellectual property developed in connection with the project and the grant he received for pre-clinical and clinical projects.
He will talk about commercialization of the product and the need for agreements and/or partnerships (of which none exist as of now). He will tell you of his plans for more studies and clinical trials. His plans for developing relationships for manufacturing and his plan for getting regulatory approval in the EU and US. His plan to seek additional funding. He will say they have no commitments for any future capital. He will reiterate how great the product is and what it has over it's competition and how huge the market is for homeostatic products. He will warn that there is substantial doubt that they will generate revenue or achieve or maintain profitability and the need for additional clinical development, financing and regulatory approval are critical; therefore he and his time are working hard and they will resubmit the necessary paperwork ASAP. Then he will say this-" We EXPECT that we will pursue approvals for use of AC5 as a hemostatic agent and wound care agent in surgical and dermatological settings, and we MAY also seek to obtain approvals for additional potential indications for use of the product, which we MAY pursue either opportunistically or once initial regulatory approval for the product is obtained."
They have already said they will run out of money by end of 2018. My guess is they will milk this until then and say they have resubmitted for FDA approval in June which is about as long as investors will tolerate since he initially said it would only delay things one or two quarters. Then FDA will take there slotted time for approval and ask them questions and they will pull the second application from consideration and this thing will be dead for good. Right about the time they "run out of money"